AltaCorp Captial Believes Valens Groworks Corp (CNQX: VGW) Won’t Stop Here

By Ryan Adsit

The Healthcare company, Valens Groworks Corp (VGWResearch Report), has received a rating update from a Wall Street analyst on April 25. On April 25, analyst David Kideckel gave a Buy rating to VGW and set a C$7.75 price target.

Kideckel has an average return of 51.3% when recommending Valens Groworks Corp.

According to, Kideckel is ranked #2261 out of 5199 analysts.

Currently, the analyst consensus on Valens Groworks Corp is a Moderate Buy with an average price target of C$7.50.

Based on Valens Groworks Corp’s latest earnings release for the quarter ending February 28, the company reported a quarterly GAAP net loss of C$6.37 million. In comparison, last year the company had a GAAP net loss of C$3.78 million.

Valens GroWorks Corp. is a biotechnology company. It is engaged in the provision of cannabis products developed from the firm’s proprietary extraction techniques.

The company’s shares closed last Monday at C$4.51, close to its 52-week high of C$4.90.